



PATENT  
ATTORNEY DOCKET NO: 50211/006002

Certificate of Mailing: Date of Deposit: August 13, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Joan Glassman  
Printed name of person mailing correspondence

Joan Glassman  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Judes Poirier	Art Unit:	1648
Serial No.:	09/500,162	Examiner:	Parkin, Jeffrey S.
Filed:	February 8, 2000	Customer No.:	21559
Title:	PHARMACOGENETIC METHODS FOR USE IN THE TREATMENT OF NERVOUS SYSTEM DISEASES		

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

USSN 09/500,162  
Atty Dkt 50211/006002

If there are any additional charges or any credits, please apply them to Deposit

Account No. 03-2095.

Respectfully submitted,




Todd Armstrong, Ph.D.  
REG. NO. 54,590

Date: 13 August 2009

For

Kristina Bieker-Brady, Ph.D., P.C.  
Reg. No. 39,109

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110-2214  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50211/006002  Serial No. 09/500,162  Applicant Judes Poirier  Filing Date February 8, 2000  Group 1648  IDS Filed August 13, 2004  Customer No. 21559		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						
(37 C.F.R. § 1.98(b))						
						
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Frisoni et al., "Apolipoprotein E ε4 Allele Frequency in Vascular Dementia and Alzheimer's Disease," <i>Stroke</i> 25:1703 (1994).					
	Frisoni et al., "Apolipoprotein E ε4 Allele in Alzheimer's Disease and Vascular Dementia," <i>Dementia</i> 5:240-242 (1994).					
	Landen et al., "Apolipoprotein E in Cerebrospinal Fluid from Patients with Alzheimer's Disease and Other Forms of Dementia Is Reduced but without Any Correlation to the apoE4 Isoform," <i>Dementia</i> 7:273-278 (1996).					
	Mahieux et al. "Response to Apolipoprotein E ε4 Allele Frequency in Vascular Dementia and Alzheimer's Disease by Frisoni et al.," <i>Stroke</i> 25: 1703-1704 (1994).					
	Oliveri et al., "Apolipoprotein E Polymorphisms and Parkinson's Disease," <i>Neuroscience Letters</i> 277:83-86 (1999).					
	Singleton et al., "No Association Between the K Variant of the Butyrylcholinesterase Gene and Pathologically Confirmed Alzheimer's Disease," <i>Human Mol. Genetics</i> 7:937-939 (1998).					
	Stengard et al., "Apolipoprotein E Polymorphism, Alzheimer's Disease and Vascular Dementia Among Elderly Finnish Men," <i>Acta Neurol. Scand.</i> 92:297-298 (1995).					
	Weatherby et al., "No Association Between APOE ε4 Allele and Outcome and Susceptibility in Primary Progressive Multiple Sclerosis," <i>J. Neurol. Neurosurg. Psychiatry</i> 68:532 (2000).					
	Whitehead et al., "Frequency of the Apolipoprotein E ε4 Allele in a Case-control Study of Early Onset Parkinson's Disease," <i>J. Neurol. Neurosurg. Psychiatry</i> 61:347-351 (1996).					
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						